RT Journal Article
SR Electronic
T1 Differences in COVID-19 Vaccination and Experiences among Patients with Hypertension in Colombia and Jamaica during the COVID-19 Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.25.24304855
DO 10.1101/2024.03.25.24304855
A1 Duncan, Jacqueline P
A1 Geng, Siyi
A1 Lindsay, Carene
A1 Ferguson, Trevor
A1 Mills, Katherine
A1 Lopez-Lopez, Jose Patricio
A1 He, Hua
A1 Lanza, Paola
A1 Williams, Makeda
A1 Tutse-Tonwe, Veronica
A1 Reyes, Mabel
A1 Campo, Alfonso
A1 Marshall, Allison
A1 Lopez-Jaramillo, Patricio
A1 Tulloch-Reid, Marshall K
YR 2024
UL http://medrxiv.org/content/early/2024/03/26/2024.03.25.24304855.abstract
AB Background COVID-19 vaccination and shielding targeted hypertensive patients in low and middle income countries. We describe the COVID-19 experiences of hypertensive patients in Colombia and Jamaica and discuss factors associated with vaccine acceptance.Methods A cross-sectional study was conducted between December 2021 and February 2022 in 4 randomly selected primary care clinics in Colombia and 10 primary care clinics in Jamaica. Participants in Colombia were randomly selected from an electronic medical record. In Jamaica consecutive participants were selected on clinic days for non-communicable diseases. Interviewer-administered questionnaires were conducted by telephone.Results 576 participants were recruited (50% Jamaica; 68.5% female). Jamaica’s participants were younger (36% vs 23% <60 years) and had a lower proportion of persons with “more than high school” education (17.2% vs 30.3%, p=0.011). Colombia’s participants more commonly tested positive for COVID-19 (24.2% vs 6.3%, p<0.001), had a family member or close friend test positive for COVID-19 (54.5% vs, 21.6%; p<0.001), experienced loss of a family member or friend due to COVID-19 (21.5% vs 7.8%, p<0.001) and had vaccination against COVID-19 (90.6% vs 46.7%, p<0.001). Fear of COVID-19 (AOR 2.71, 95% CI 1.20-6.13) and residence in Colombia (AOR 5.88 (95% CI 2.38-14.56) were associated with COVID-19 vaccination. Disruption in health services affecting prescription of medication or access to doctors was low (<10%) for both countries.Conclusion Health services disruption was low but COVID-19 experiences such as fear of COVID-19 and vaccine acceptance differed significantly between Colombia and Jamaica. Addressing reasons for these differences are important for future pandemic responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: This work was supported by the National Heart, Lung, and Blood Institute (4UH3HL152373). Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Tulane University Institutional Review Board (USA), Institutional Bioethics Committee of Universidad de Santander (Colombia) and the University of the West Indies (UWI) Mona Campus Research Ethics Committee (Jamaica).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors